R&D
Incredible progress in biological and technological sciences and the untapped potential in herbs are kept in mind during development and capacity enhancement projects at PannonPharma group.
Incredible progress in biological and technological sciences and the untapped potential in herbs are kept in mind during development and capacity enhancement projects at Pannonpharma Group.
Tools and techniques available for research and development activities in the field of biotechnology:
o In vitro cell and 2D, 3D tissue culture engineering, confocal microscopy, molecular biological techniques e.g. electrophoresis, PCR
o Fermentation, cell banking, biological assay
o Virus production capacity (Fertilized egg, Class I)
Primycin, the only original Hungarian antibiotic, which was first described in Nature by Vályi-Nagy et al. in 1954, is in the focus of research and development activities. Primycin is the active substance of Ebrimycin® gel, which was first marketed by Chinoin Inc. in 1982. Rights of the medicinal product and the active substance were in-licensed by Pannonpharma Ltd. in 2003. Two new patents and numerous scientific articles, diploma and PhD thesis have been published in the field of primycin as a result of several years of research and development work and cooperation.
Primycin is a potential candidate against multiresistant Gram-positive pathogens as a result of re-evaluation of in vitro antibacterial activity.
Production site at Pécsvárad possesses GMP certificate for manufacturing and packaging of investigational medicinal products for clinical trials (solid and liquid dosage forms, non-sterile).
Pannonpharma Ltd. is a member of the Hungarian Biotechnology Association and the accredited Biotechnology Innovation Base Cluster located in Southern Transdanubia.
